Compare SAP SE (SAP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Summit Therapeutics Inc — how do they compare? SAP SE trades at $203.72 (market cap $240.81B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: SAP SE is far larger — about 20× Summit Therapeutics Inc's market cap, and SAP SE pays a 1.4% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SAP | SMMT | |
|---|---|---|
Market Cap | $240.81B | $12.06B |
Sector | Technology | Health |
52-Week High | $280.46 | $26.98 |
52-Week Low | $146.38 | $12.55 |
Enterprise Value | $239.52B | $11.39B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP trades at $204.035, down 2.16% today, with a bullish technical trend supported by moving averages but overbought RSI signals. Revenue grew to $36.8B in 2025 with a strong net income margin of 20.41%, though Q2 2026 EPS missed estimates. Recent news highlights AI and cloud momentum, with shares reacting positively to Q2 results despite profit guidance concerns.
Outlook is cautiously optimistic with a consensus price target of $209.67, offering modest upside. Risks include execution challenges in AI integration and margin pressure from rising costs. The stock presents a growth opportunity driven by cloud adoption, but investors should weigh valuation multiples against earnings consistency.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
